HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
HeartBeam completed enrollment ahead of schedule in its HEADSTART-ACS study, the largest heart attack detection study using its technology, with 486 patients enrolled at Indonesia's National Cardiovascular Center Harapan Kita. Data analysis is underway with results expected at a cardiology conference in 2027; together with the 132-patient ALIGN-ACS pilot, HeartBeam now has clinical experience with more than 600 patients ahead of its U.S. pivotal study planned for Q1 2027.
Key figures
- Drug Name
- HeartBeam System (3D ECG)
- Phase Of Trial
- Investigational study (HEADSTART-ACS); U.S. pivotal study planned Q1 2027
- Patients align pilot
- 132
- Patients enrolled headstart
- 486
- Total patients across studies
- more than 600
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.